Advanced Biomed’s Nasdaq Debut Fuels $6.56M IPO and NMPA-Cleared Cancer Biochips

Introduction to Advanced Biomed Inc.

Advanced Biomed Inc. (NASDAQ: ADVB) is a Nasdaq-listed biotechnology company headquartered in Tainan, Taiwan. Since its incorporation in 2014, the company has developed a proprietary microfluidic technology platform that combines semiconductor engineering with biochip design. Its primary focus is on early screening, detection, diagnosis, staging, and treatment of cancer through precision tumor analysis.

Corporate Structure and Workforce

Advanced Biomed Inc. is organized as a Nevada-incorporated holding company, with primary operations, design, and development conducted in Taiwan. The company maintains subsidiaries in Hong Kong and Mainland China, and it is preparing to establish operating centers in North America and Europe. According to its LinkedIn profile, the workforce comprises 11 to 50 employees, covering roles in research and development, chip design, clinical affairs, manufacturing, and administration.

Biotechnology by Louis Reed

Developments and News

On March 6, 2025, Advanced Biomed Inc. began trading on the Nasdaq Capital Market under the ticker symbol ADVB. On March 7, 2025, the company closed its initial public offering of 1,640,000 common shares at a price of US $4.00 per share, raising gross proceeds of US $6.56 million before underwriting discounts and offering expenses. The underwriter was granted a 45-day option to purchase up to 246,000 additional shares at the same price, less discounts and commissions.

Proceeds from the offering are allocated to:

• In vitro diagnostics (IVD) clinical research, chip design and development, and facility upgrades
• Marketing, sales expansion, and entry into new markets
• General working capital

During pre-mass production trials, the A+Pre biochip achieved a tumor cell recovery rate of 94%, while the AC-1000 enrichment chip reached 79.5%. Both devices have received clearance from China’s National Medical Products Administration (NMPA). Advanced Biomed plans to initiate clinical research for its A+LCGuard lung cancer screening kit by mid-2025 and to support localized production and regulatory filings in North America and Europe.

Financial and Strategic Analysis

As of October 12, 2023, the ADVB share price is US $0.47, reflecting a 28.21% increase for the day, with a trading volume of 572,229 shares. The company’s market capitalization stands at approximately US $7.9 million. According to available filings, Advanced Biomed held US $2.66 million in cash and had a debt-to-equity ratio of 56.65% as of its most recent quarter. It reported negative net income and levered free cash flow of –US $4.84 million over the trailing twelve months.

Strategically, Advanced Biomed utilizes its integrated microfluidic platform to capture and analyze circulating tumor cells without reliance on antibody markers, which may expand its applicability across various tumor types. The company’s device portfolio—A+Pre, AC-1000, A+CellScan, and A+SCDrop—addresses distinct stages of liquid biopsy workflows, from sample preparation to single-cell sorting.

Market Position and Industry Context

Advanced Biomed operates in the precision oncology diagnostics sector, where demand for non-invasive liquid biopsy solutions is growing. Its semiconductor-based, antigen-independent approach differentiates it from competitors that primarily rely on circulating tumor DNA analysis or antibody-based techniques. Regional expansions in Greater China, North America, and Europe align with projected market growth rates exceeding 15% annually for cancer diagnostics platforms through 2030. Strategic partnerships with chip manufacturers and regulatory clearances in China support the company’s efforts to scale production and enter key markets.

tl;dr

Advanced Biomed Inc. completed a US $6.56 million IPO on March 7, 2025, and began trading on Nasdaq on March 6, 2025. The company reported biochip recovery rates of 94% for A+Pre and 79.5% for AC-1000 in pre-mass production trials, with both devices cleared by China’s NMPA. As of mid-2025, proceeds will fund IVD clinical research, chip design, facility upgrades, and market expansion. Clinical research for the A+LCGuard lung cancer screening kit is slated for mid-2025, alongside preparations for North American and European regulatory filings and localized production.